ZA202310013B - Chelators for radiometals and methods of making and using same - Google Patents
Chelators for radiometals and methods of making and using sameInfo
- Publication number
- ZA202310013B ZA202310013B ZA2023/10013A ZA202310013A ZA202310013B ZA 202310013 B ZA202310013 B ZA 202310013B ZA 2023/10013 A ZA2023/10013 A ZA 2023/10013A ZA 202310013 A ZA202310013 A ZA 202310013A ZA 202310013 B ZA202310013 B ZA 202310013B
- Authority
- ZA
- South Africa
- Prior art keywords
- making
- methods
- radiometals
- chelators
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185951P | 2021-05-07 | 2021-05-07 | |
| PCT/CA2022/050712 WO2022232943A1 (en) | 2021-05-07 | 2022-05-06 | Chelators for radiometals and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202310013B true ZA202310013B (en) | 2024-05-30 |
Family
ID=83931919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/10013A ZA202310013B (en) | 2021-05-07 | 2023-10-26 | Chelators for radiometals and methods of making and using same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240254085A1 (enExample) |
| EP (1) | EP4334290A4 (enExample) |
| JP (1) | JP2024517879A (enExample) |
| AU (1) | AU2022271362A1 (enExample) |
| CA (1) | CA3217801A1 (enExample) |
| WO (1) | WO2022232943A1 (enExample) |
| ZA (1) | ZA202310013B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024235273A1 (zh) * | 2023-05-15 | 2024-11-21 | 成都社泰医疗科技有限公司 | 多靶向化合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020186328A1 (en) * | 2019-03-20 | 2020-09-24 | The University Of British Columbia | Chelators and methods of making and using same |
-
2022
- 2022-05-06 CA CA3217801A patent/CA3217801A1/en active Pending
- 2022-05-06 JP JP2023568386A patent/JP2024517879A/ja active Pending
- 2022-05-06 US US18/559,132 patent/US20240254085A1/en active Pending
- 2022-05-06 EP EP22798482.0A patent/EP4334290A4/en active Pending
- 2022-05-06 AU AU2022271362A patent/AU2022271362A1/en active Pending
- 2022-05-06 WO PCT/CA2022/050712 patent/WO2022232943A1/en not_active Ceased
-
2023
- 2023-10-26 ZA ZA2023/10013A patent/ZA202310013B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240254085A1 (en) | 2024-08-01 |
| JP2024517879A (ja) | 2024-04-23 |
| WO2022232943A1 (en) | 2022-11-10 |
| CA3217801A1 (en) | 2022-11-10 |
| EP4334290A4 (en) | 2026-01-28 |
| EP4334290A1 (en) | 2024-03-13 |
| AU2022271362A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1601384T3 (pl) | Sposoby radiofluorowania biologicznie czynnych wektorów | |
| MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
| PH12022550124A1 (en) | Enzyme inhibitors | |
| AU2483000A (en) | Treatment of asthma with mek inhibitors | |
| MX2010010151A (es) | Moduladores de cinasa aurora y metodo de uso. | |
| NZ545935A (en) | Method of treating cancer with HDAC inhibitors | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| AP1699A (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| PA8539801A1 (es) | Derivados del ácido isoftálico como inhibidores de metaloproteinasas de la matriz | |
| NZ517616A (en) | Use of retigabin for treating neuropathic pain | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| NO20083207L (no) | Inhibitorer av IAP | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| SE0202539D0 (sv) | Compounds | |
| MXPA05005146A (es) | Indolpiridinio sustituido como compuestos antiinfecciosos. | |
| MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| MX2022002069A (es) | Inhibidores de enzimas. | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| MX2024015922A (es) | Degradadores de proteinas del factor 2 relacionado con el eritroide de factor nuclear 2 (nrf2) | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. | |
| ZA202203360B (en) | Peptide amide composition and preparation method therefor | |
| IL173377A0 (en) | Compounds for the treatment of metabolic disorders | |
| NZ547795A (en) | 3-Cyano-quinoline derivatives with antiproliferative activity | |
| SI1511472T1 (sl) | Spojine uporabne pri zdravljenju antraksa in inhibiranju letalnega faktorja | |
| MX2010005787A (es) | Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina. |